In the context of secondary AKI, in experimental rodent models of AP-MODS, in which AKI is an important contributor, pharmacological inhibition of KMO, and separately, transcriptional blockade of the Kmo gene, reduces 3-hydroxykynurenine formation and protects against AKI12–15. Here, KMO is linked to acute kidney injury.